早期の術後の肝機能異常のリスク要因と予測モデリング
Lin Zhong1, Hao-Yuan Wang1, Xiao-Na Li2
1Second Clinical Hospital of Guangzhou University of Chinese Medicine, Guangzhou 510120, Guangdong Province, China.
World journal of hepatology
|September 3, 2025
まとめ
手術前における肝臓酵素の上昇,血小板の減少,およびセボフルランの使用は,手術後の肝臓機能障害の主要な危険因子です. 新しいモデルは様々な手術で 肝臓損傷のリスクを 効果的に予測しています
科学分野:
- アネステシオロジーと手術前医学
- ヘパトロジー
- 手術 結果 研究
背景:
- 非肝臓および非心臓手術における手術後の異常肝機能に影響を与える要因に関する研究は限られている.
- これらの要因を理解することは 患者の治療結果を改善し 標的を絞った介入策を策定する上で 極めて重要です
研究 の 目的:
- 早期の手術後の異常な肝機能の危険因子を特定する.
- 手術後の肝機能障害の予測モデルを開発し,検証する.
主な方法:
- 5つの外科部門から3720人の患者を対象に実施された遡及コホート研究.
- ロジスティック回帰とLASSO分析により,リスク要因が特定され,予測モデルが構築されました.
- モデルの性能は,ホスマー・レメショーテストとROC曲線解析を用いて評価された.
主要な成果:
- 肝臓機能の異常を予測する主な要因は,手術前のアスパルテートアミノトランスフェラーゼ (AST) とアラニンアミノトランスフェラーゼ (ALT) の値上昇,血小板数の減少です.
- 術内セボフルーランの使用も重大なリスク因子として特定されました.
- 開発された予測モデルは強力な予測効果と良好な校正を示した.
結論:
- 術前の肝臓酵素の上昇,血小板数の低下,セボフルランの使用は,術後の肝臓損傷の重要な危険因子です.
- 確立されたリスク予測モデルは,肝臓機能障害のリスクのある患者を特定する上で強力な有効性を示しています.
関連する概念動画
01:16Hepatic Drug Excretion: Influencing Factors
826
The biliary system of the liver, crucial for bile secretion and drug excretion, comprises intrahepatic bile ducts that merge to form the common hepatic duct. This duct, carrying hepatic bile, combines with the cystic duct, draining the gallbladder and forming the common bile duct, which empties into the duodenum. Bile, produced by hepatic cells lining the bile canaliculi, is composed primarily of water, bile salts, pigments, electrolytes, and lesser amounts of cholesterol and fatty acids. Bile...
826
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
386
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
386
01:14Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug
360
In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
360
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
274
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
274
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
387
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
387
01:24Drug Toxicity: Risk factors
248
Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...
248